Atossa TherapeuticsATOS
13F holders, Q4 2025 (December 31)1holders
1new positions
0sold out
$0.59avg. 13F price*
At the end of Q4 2025, 1 institutions reported holding Atossa Therapeutics Inc. (ATOS) in their 13F filings, unchanged from Q2 2025. 1 opened new positions and 0 sold out. The largest holder was Marshall Wace, LLP ($17K).
- Company
- Atossa Therapeutics Inc.
- CUSIP
- 04962H704
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $17K |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q4 2025: 28,072 shares bought, net +28,072 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Marshall Wace, LLP | 0.00% | New | 28,072 | $17K |
"% of holder's portfolio" is ATOS's weight in each manager's 13F, not the share of Atossa Therapeutics Inc. the manager owns.